A laboratory technician prepares COVID-19 patient samples for semi-automatic testing at Northwell Health Labs, Wednesday, March 11, 2020, in Lake Success, N.Y. The US Food and Drug Administration has approved faster testing protocols as the viral outbreak continues to spread worldwide. For most people, the new coronavirus causes only mild or moderate symptoms. For some it can cause more severe illness.
John Minchillo / AP Photo
John Minchillo / AP Photo
A laboratory technician prepares COVID-19 patient samples for semi-automatic testing at Northwell Health Labs, Wednesday, March 11, 2020, in Lake Success, N.Y. The US Food and Drug Administration has approved faster testing protocols as the viral outbreak continues to spread worldwide. For most people, the new coronavirus causes only mild or moderate symptoms. For some it can cause more severe illness.
(Washington) — The Biden administration has made a $231.8 million deal with an Australian company to boost availability of the first at-home rapid test for the coronavirus which causes COVID-19 that is available without a prescription. The test, made by Ellume, can send results to a smartphone within 15 minutes of receiving a sample.
The Food and Drug Administration gave emergency authorization to Ellume’s rapid test in December, after it showed 96% accuracy in a U.S. clinical study. Those trials included both adults and children of ages 2 years and older.
The company received $30 million in October from the U.S. National Institutes of Health Rapid Acceleration of Diagnostics initiative to support clinical testing and manufacture of the test.
As part of the new contract, Ellume has committed to providing 8.5 million tests to the federal government, said Andy Slavitt, senior advisor to the White House COVID-19 Response Team.
Ellume says it will build its first U.S.-based factory to make the tests, ramping up toward producing 19 million kits each month later this year.
The test uses a relatively short nasal swab to collect a sample. The sample is put into a digital analyzer linked to a smartphone app. In December, the company told NPR the test would be available for about $30.
Sometimes, your mornings are just too busy to catch the news beyond a headline or two. Don’t worry. The Morning Agenda has got your back. Each weekday morning, host Tim Lambert will keep you informed, amused, enlightened and up-to-date on what’s happening in central Pennsylvania and the rest of this great commonwealth.
